



**LIST OF ART CITED BY APPLICANT**

ATTY. DOCKET: 17679 (BOT)	SERIAL NO.: 10/789,180
APPLICANT: Catherine Turkel et al.	TITLE: METHODS FOR TREATING PAIN AND FOR TREATING A MEDICATION OVERUSE DISORDER
FILING DATE: February 26, 2004	GROUP:

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
AA	10/194,805		Donovan, Stephen			7/11/2002
AB	10/423,380		Ackerman, Alan H.			4/25/2003
AC	10/429,069		Voet, Martin A.			5/2/2003
AD	10/630,587		Aoki et al.			7/29/2003
AE	10/731,973		First, Eric R.			12/9/2003
AF	10/752,869		First, Eric R.			1/6/2004
AG	60/418,789		Katz, Howard			10/15/2002
AH	2003 0224019	12/4/2003	Christopher O'Brien			
AI	5,437,291	8/1/1995	Pasricha et al.			
AJ	5,670,484	9/23/1997	William J. Binder			
AK	5,714,468	2/3/1998	William J. Binder			
AL	5,766,605	6/16/1998	Sanders et al.			
AM	5,989,545	11/23/1999	Foster et al.			
AN	6,063,768	5/16/2000	Eric R. First			
AO	6,139,845	10/31/2000	Stephen Donovan			
AP	6,299,893	10/9/2001	Schwartz et al.			
AQ	6,306,423	10/23/2001	Donovan et al.			
AR	6,312,708	11/6/2001	Stephen Donovan			
AS	6,358,917	3/19/2002	Carruthers et al.			
AT	6,423,319	7/23/2002	Brooks et al.			
AU	6,447,787	9/10/2002	Gassner et al.			
AV	6,458,365	10/1/2002	Aoki et al.			
AW	6,464,986	10/15/2002	Aoki et al.			
AX	6,623,742	9/23/2003	Martin A. Voet			

EXAMINER

DATE CONSIDERED

9/10/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF ART CITED BY APPLICANT**

ATTY. DOCKET: 17679 (BOT)	SERIAL NO.: 10/789,180
APPLICANT: Catherine Turkel et al.	TITLE: METHODS FOR TREATING PAIN AND FOR TREATING A MEDICATION OVERUSE DISORDER
FILING DATE: February 26, 2004	GROUP:

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA	DE 101 50 415	5/15/2003	Germany			N
<i>Jyf</i>	BK	A1 WO 03/011333	2/13/2003	PCT			Y

**OTHER ART**

(Including Author, Title, Date, Pertinent Pages, etc.)

<i>Jyf</i>	CA	Aoki K., et al, <i>Mechanisms of the antinociceptive effect of subcutaneous Botox: Inhibition of peripheral and central nociceptive processing</i> , Cephalgia 2003 Sep;23(7):649
	CB	Aoki, K., et al., <i>Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions</i> , Eur J. Neurol 2001: (suppl 5); 21-29
	CC	Aoki, K., <i>Physiology and pharmacology of therapeutic botulinum neurotoxins</i> , in Kreyden, O., editor, <i>Hyperhydrosis and botulinum toxin in dermatology</i> , Basel, Karger; 2002; 30: pages 107-116, at 109-110
	CD	Bhattacharya K., et al., <i>Novel uses of botulinum toxin type A: two case reports</i> , Mov Disord 2000; 15(Suppl 2):51-52
	CE	Bigalke H., et al., <i>Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture</i> , Brain Research 360;318-324:1985
	CF	Bigalke H., et al., <i>Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations From Rat Brain and Spinal Cord</i> , Naunyn-Schmiedeberg's Arch Pharmacol 316;244-251:1981
	CG	Binz T. et al., <i>The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins</i> , J Biological Chemistry 265(16):9153-9158:1990
<i>✓</i>	CH	Blugerman G., et al., <i>Multiple eccrine hidrocystomas: A new therapeutic option with botulinum toxin</i> , Dermatol Surg 2003 May;29(5):557-9

EXAMINER

DATE CONSIDERED

*09/10/04*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17679 (BOT)	SERIAL NO.:	10/789,180
APPLICANT:	Catherine Turkel et al.	TITLE:	METHODS FOR TREATING PAIN AND FOR TREATING A MEDICATION OVERUSE DISORDER
FILING DATE:	February 26, 2004	GROUP:	

<i>VJ</i>	CI	Brem, H., et al, <i>Placebo-Controlled Trial of Safety and Efficacy of Intraoperative Controlled Delivery by Biodegradable Polymers of Chemotherapy for Recurrent Gliomas</i> , Lancet 345;1008-1012:1995
	CJ	Brin, M., et al., <i>Botulinum toxin type A: pharmacology</i> , in Mayer N., editor, Spasticity: etiology, evaluation, management and the role of botulinum toxin, 2002; pages 110-124, at 112-113
	CK	Bushara K., <i>Botulinum toxin and rhinorrhea</i> , Otolaryngol Head Neck Surg 1996;114(3):507
	CL	Cui, M., et al., <i>Mechanisms of the antinociceptive effect of subcutaneous BOTOX®: inhibition of peripheral and central nociceptive processing</i> , Naunyn Schmiedebergs Arch Pharmacol 2002; 365 (supp 2): R17
	CM	Dabrowski et al.; <i>Botulinum toxin as a novel treatment for self mutilation in Lesch-Nyhan syndrome</i> , Ann Neurol 2002 Sep;52(3 Supp 1):S157
	CN	Duggan et al.; A survey of Botulinum neurotoxin substrate expression in cells; <i>Mov Disord</i> , 10(3):376:1995
	CO	Fung L. K. et al., <i>Pharmacokinetics of Interstitial Delivery of Carmustine 4-Hydroperoxycyclophosphamide and Paclitaxel From a Biodegradable Polymer Implant in the Monkey Brain</i> , Cancer Research 58;672-684:1998
	CP	Gonelle-Gispert et al.; snap-25a and -25b isoforms are both expressed in insulin-secreting cells and can function in insulin secretion; <i>Biochem J</i> 1;339 (pt 1):159-65:1999
	CQ	Guyton A.C. et al., <i>Textbook of Medical Physiology</i> , W.B. Saunders Company 1996, ninth edition; 686-688
	CR	Habermann E., et al., <i>Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release From Cultured Mouse Brain</i> , J Neurochem 51(2):522-527:1988
	CS	Habermann E., <i>Inhibition by Tetanus and Botulinum A Toxin of the release of [<sup>3</sup>H]Noradrenaline and [<sup>3</sup>H]GABA From Rat Brain Homogenate</i> , Experientia 44;224-226: 1988
<i>V</i>	CT	Habermann, I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation, Binding to Synaptosomes and Ascent to the Spinal Cord; <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> 1974; 281: 47-56

EXAMINER

DATE CONSIDERED

*Vanna M* 9/10/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF ART CITED BY APPLICANT**

ATTY. DOCKET:	17679 (BOT)	SERIAL NO.:	10/789,180
APPLICANT:	Catherine Turkel et al.	TITLE:	METHODS FOR TREATING PAIN AND FOR TREATING A MEDICATION OVERUSE DISORDER
FILING DATE:	February 26, 2004	GROUP:	

<i>[Signature]</i>	CU	Harrison's Principles of Internal Medicine (1998), edited by Anthony Fauci et al., 14 <sup>th</sup> edition, published by McGraw Hill
	CV	Heckmann M., et al., <i>Botulinum toxin type A injection in the treatment of lichen simplex: An open pilot study</i> , J Am Acad Dermatol 2002 Apr;46(4):617-9
	CW	Jacks, L., et al., <i>Idiopathic toe walking: Treatment with botulinum toxin A injection</i> , Dev Med Child Neurol 2002;44(Suppl 91):6), and foot dystonia (Rogers J., et al., <i>Injections of botulinum toxin A in foot dystonia</i> , Neurology 1993 Apr;43(4 Suppl 2
	CX	Jahanshahi M., et al., <i>Psychological functioning before and after treatment of torticollis with botulinum toxin</i> , J Neurol Neurosurg Psychiatry 1992; 55(3): 229-231
	CY	Jankovic J. et al., <i>Therapy With Botulinum Toxin</i> , Marcel Dekker, Inc., (1994), page 5, 150
	CZ	Jost W., <i>Ten years' experience with botulinum toxin in anal fissure</i> , Int J Colorectal Dis 2002 Sep;17(5):298-302
	CAA	Katsambas A., et al., <i>Cutaneous diseases of the foot: Unapproved treatments</i> , Clin Dermatol 2002 Nov-Dec;20(6):689-699
	CBB	Li Y., et al., <i>Sensory and motor denervation influences epidermal thickness in rat foot glabrous skin</i> , Exp Neurol 1997;147:452-462 (see page 459)
	CCC	Marjama-Lyons, J., et al., <i>Tremor-Predominant Parkinson's Disease</i> , Drugs & Aging 16(4):273-278:2000
	CDD	Moyer E et al., <i>Botulinum Toxin Type B: Experimental and Clinical Experience</i> , being chapter 6, pages 71-85 of "Therapy With Botulinum Toxin", edited by Jankovic, J. et al. (1994), Marcel Dekker, Inc.
	CEE	Murry T., et al., <i>Spasmodic dysphonia; emotional status and botulinum toxin treatment</i> , Arch Otolaryngol 1994 Mar; 120(3): 310-316
	CFF	Naumann et al; Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions; <i>European J. Neurology</i> 6 (Supp 4): S111-S1150:1999
	CGG	Pearce, L.B., <i>Pharmacologic Characterization of Botulinum Toxin For Basic Science and Medicine</i> , Toxicon 35(9);1373-1412 at 1393
	CHH	Ragona et al., <i>Management of Parotid Sialocele With Botulinum Toxin; The Laryngoscope</i> 109:1344-1346, 1999
<i>[Signature]</i>	CI	Sanchez-Prieto, J., et al., <i>Botulinum Toxin A Blocks Glutamate Exocytosis From Guinea Pig Cerebral Cortical Synaptosomes</i> , Eur J. Biochem 165,675-681:1897

EXAMINER Vanessa Ford DATE CONSIDERED 09/10/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF ART CITED BY APPLICANT**

ATTY. DOCKET:	17679 (BOT)	SERIAL NO.:	10/789,180
APPLICANT:	Catherine Turkel et al.	TITLE:	METHODS FOR TREATING PAIN AND FOR TREATING A MEDICATION OVERUSE DISORDER
FILING DATE:	February 26, 2004	GROUP:	

<i>MJ</i>	CJJ	Schantz, E.J., et al, <i>Properties and use of Botulinum toxin and Other Microbial Neurotoxins in Medicine</i> , Microbiol Rev. 56;80-99:1992
	CKK	Sevim, S., et al., <i>Botulinum toxin-A therapy for palmar and plantar hyperhidrosis</i> , Acta Neurol Belg 2002 Dec;102(4):167-70
	CLL	Singh, <i>Critical Aspects of Bacterial Protein Toxins</i> , pages 63-84 (chapter 4) of <i>Natural Toxins II</i> , edited by B.R. Singh et al., Plenum Press, New York (1976)
	CMM	Suputtipatada, A., <i>Local botulinum toxin type A injections in the treatment of spastic toes</i> , Am J Phys Med Rehabil 2002 Oct;81(10):770-5
	CNN	Weigand et al., <i>I-Labelled Botulinum A Neurotoxin: Pharmacokinetics in Cats after Intramuscular Injection</i> ; Nauny-Schmiedeberg's Arch. Pharmacol. 1976; 292, 161-165
<i>✓</i>	COO	Woolf C. et al., <i>Neuropathic Pain: Aetiology, Symptoms, Mechanisms, and Management</i> , Lancet 1999; 353: 1959-64

EXAMINER



DATE CONSIDERED

9/10/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.